Eisai, Solstice Ink European Copromotion Deal For Botox Competitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms also plan to seek several non-cosmetic indications for the biologic, for which clinical trials have shown some advantages over Allergan’s Botox, Solstice CEO tells “The Pink Sheet” DAILY.